Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|June 21, 2017
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-07-05-2017
- Volume 12
- Issue 7
FUJIFILM Announces Completion of 100th Program Using Protein Expression System
Author(s)Pharmaceutical Technology Editors
The company announced that it has completed its 100th program using the pAVEway protein expression system, which was originally introduced to the market in 2007.
Advertisement
On June 20, 2017, FUJIFILM Diosynth Biotechnologies announced the completion of its 100th program using pAVEway Advanced Protein Expression system. The expression system was originally introduced to the market during the 2007 BIO International Convention in Boston, Massachusetts.
pAVEway was developed by FUJIFILM Diosynth Biotechnologies to enable the reliable and scalable GMP manufacturing of E.coli -based processes. The pAVEway system has the ability to control protein expression by allowing expression and secretion to be coupled. It also allows for slower expression, which can result in a higher chance of folding, and to sustain accumulation for many hours with continued cell growth. The system is suited to investigate difficult-to-express proteins with protein toxicity to the cells.
Source: FUJIFILM
Articles in this issue
over 9 years ago
Overcoming Concerns to Adopting Continuous Processesover 9 years ago
The Search for Efficient Synthesis of Complex Cannabinoidsover 9 years ago
BASF Ups Ibuprofen Capacities in Germany and North Americaover 9 years ago
Itzhak Krinsky Joins Halo Pharma Board of Directorsover 9 years ago
Survey Reveals that Blockchain will be Adopted Within Five Yearsover 9 years ago
Agilent Adds Products to InfinityLab LC SeriesAdvertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Can Continuous Tableting End Scale-Up for Complex Oral Drugs?
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
5